Hypoxia related growth factors and p53 in preoperative sera from patients with colorectal cancer - evaluation of the prognostic significance of these agents

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 11, 2009, Pages 1439-1445

  Sulkowski, Stanislaw ^a   Wincewicz, Andrzej ^a   Zalewski, Bogdan ^a   Famulski, Waldemar ^a   Lotowska, Joanna Maria ^a   Koda, Mariusz ^a   Sobaniec Lotowska, Maria Elzbieta ^a   Mysliwiec, Michal ^a   Baltaziak, Marek ^a   Pawlak, Krystyna ^a   Sulkowska, Mariola ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Colorectal cancer; Insulin like growth factor I; P53; Serum; Vascular endothelial growth factor

Indexed keywords

PROTEIN P53; SOMATOMEDIN C; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; PROTEIN METABOLISM;

CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 73349128444     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.305     Document Type: Article

References (38)

1. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 1998;58:4008-4014
2. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002;277:15600-15606
3. Miyamoto S, Nakamura M, Shitara K, Nakamura K, Ohki Y, Ishii G, et al. Blockade of paracrine supply of insulinlike growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 2005;11:3494-3502
4. Gupta S, Bhatia A. Morphological and immunohistochemical spectrum in anorectal malignancies. Indian J Med Res 1994;99:173-178
5. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002;277:38205-38211
6. Takahashi Y, Tucker SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997;132:541-546
7. Sulkowska M, Famulski W, Wincewicz A, Moniuszko T, Kedra B, Koda M, et al. Levels of VE-cadherin increase independently of VEGF in preoperative sera of patients with colorectal cancer. Tumori 2006;92:67-71.
8. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, et al. Acutephase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 2008;46:359-364
9. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004;100:270-278
10. Brausewetter F, Jehle PM, Jung MF, Boehm BO, Brueckel J, Hombach V, et al. Microvascular permeability is increased in both types of diabetes and correlates dif ferentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF). Horm Metab Res 2001;33:713-720
11. Amin AF, Abd el-Aal DE, Darwish AM, Meki AR. Evaluation of the impact of laparoscopic ovarian drilling on Doppler indices of ovarian stromal blood flow, serum vascular endothelial growth factor, and insulin-like growth factor-1 in women with polycystic ovary syndrome. Fertil Steril 2003;79:938-941
12. Nagai Y, Ando H, Nohara E, Yamashita H, Takamura T, Kobayashi K. Plasma levels of vascular endothelial growth factor in patients with acromegaly. Horm Metab Res 2000;32:326-329
13. Famulski W, Sulkowska M, Wincewicz A, Kedra B, Pawlak K, Zalewski B, et al. p53 correlates positively with VEGF in preoperative sera of colorectal cancer patients. Neoplasma 2006;53:43-48
14. Levesque MA, D'Costa M, Diamandis EP. p53 protein is absent from the serum of patients with lung cancer. Br J Cancer 1996;74:1434-1440
15. Paluszkiewicz P, Berbeć H, Pawłowska-Wakowicz B, Cybulski M, Paszkowska A. p53 protein accumulation in colorectal cancer tissue has prognostic value only in leftsided colon tumours. Cancer Detect Prev 2004;28:252-9.
16. Darmon E, Cleary KR, Wargovich MJ. Immunohistochemical analysis of p53 overexpression in human colonic tumors. Cancer Detect Prev 1994;18:187-195
17. Anthony FW, Evans PW, Wheeler T, Wood PJ. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem 1997;34:276-280
18. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000;6:3147-3152
19. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62: 1030-1035
20. Koda M, Reszec J, Sulkowska M, Kanczuga-Koda L, Sulkowski S. Expression of the insulin-like growth factor-I receptor and proapoptotic bax and bak proteins in human colorectal cancer. Ann NY Acad Sci 2004;1030: 377-383
21. Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med 2000;342:124-125
22. Razmus I, Jackson J, Wilson D. Hereditary non-polyposis colon cancer: change the name to protect the innocent. Medsurg Nurs 2008;17:400-4, 410.
23. Stigliano V, Assisi D, Cosimelli M, Palmirotta R, Giannarelli D, Mottolese M, et al. Survival of hereditary nonpolyposis colorectal cancer patients compared with sporadic colorectal cancer patients. J Exp Clin Cancer Res 2008;27:39.
24. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004;3:93-100.
25. Hursting SD, Lavigne JA, Berrigan D, Donehower LA, Davis BJ, Phang JM, et al. Diet-gene interactions in p53- deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr 2004;134:2482S-6S.
26. Perfetti R, Lee-Kwon W, Montrose-Rafizadeh C, Bernier M. Overexpression and activation of the insulin receptor enhances expression of ERCC-1 messenger ribonucleic acid in cultured cells. Endocrinology 1997;138:1829-1835
27. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003;63:4384-4388
28. Zusman I, Vol A, Kozlenko M. Polymorphism of cellular physicochemical [correction of physiocochemical] features and cancer. In Vivo 2000;14:683-689
29. Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;58:2288-2292
30. Takahashi Y, Bucana CD, Cleary KR, Ellis LM. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer 1998;79:34-38
31. Kieser A, Weich HA, Brandner G, Marmé D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-969
32. Leri A, Liu Y, Claudio PP, Kajstura J, Wang X, Wang S, et al. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol 1999;154:567-580
33. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 1996;93:8318-8323
34. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004 Jan 15;100:270-278
35. Karayiannakis AJ, Syrigos KN, Zbar A, Baibas N, Polychronidis A, Simopoulos C, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002 May;131:548-555
36. Werther K, Christensen IJ, Nielsen HJ. Danish RANX05 Colorectal Cancer Study Group. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002 Feb 1;86:417-423
37. Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 2005;20:203-220
38. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-2019